Juno Therapeutics EBITDA vs. Current Liabilities
Based on Juno Therapeutics' profitability indicators, Juno Therapeutics may not be well positioned to generate adequate gross income at the moment. It has a very high risk of underperforming in May. Profitability indicators assess Juno Therapeutics' ability to earn profits and add value for shareholders.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.
Please note, there is a significant difference between Juno Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Juno Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Juno Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
For Juno Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Juno Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Juno Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Juno Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Juno Therapeutics over time as well as its relative position and ranking within its peers.
Juno |
Juno Therapeutics Current Liabilities vs. EBITDA Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Juno Therapeutics's current stock value. Our valuation model uses many indicators to compare Juno Therapeutics value to that of its competitors to determine the firm's financial worth. Juno Therapeutics is rated below average in ebitda category among related companies. It is rated below average in current liabilities category among related companies . Comparative valuation analysis is a catch-all model that can be used if you cannot value Juno Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Juno Therapeutics' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Juno Therapeutics' earnings, one of the primary drivers of an investment's value.Juno Current Liabilities vs. EBITDA
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Juno Therapeutics |
| = | (350.85 M) |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Juno Therapeutics |
| = | 119.73 M |
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
Juno Current Liabilities Comparison
Juno Therapeutics is currently under evaluation in current liabilities category among related companies.
Juno Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Juno Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Juno Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Juno Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Juno Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Juno Therapeutics, Inc., a biopharmaceutical company, engages in developing cell-based cancer immunotherapies. Juno Therapeutics, Inc. was founded in 2013 and is headquartered in Seattle, Washington. Juno Therapeutics operates under Biotechnology classification in USA and traded on NASDAQ. It employs 589 people.
Juno Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Juno Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Juno Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Juno Therapeutics' important profitability drivers and their relationship over time.
Use Juno Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Juno Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Juno Therapeutics will appreciate offsetting losses from the drop in the long position's value.Juno Therapeutics Pair Trading
Juno Therapeutics Pair Trading Analysis
The ability to find closely correlated positions to Equifax could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Equifax when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Equifax - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Equifax to buy it.
The correlation of Equifax is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Equifax moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Equifax moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Equifax can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Juno Therapeutics position
In addition to having Juno Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Power Assets Thematic Idea Now
Power Assets
Large capitalization equities showing high long-term performance indicators and above average return expectations based on Macroaxis rating system. The Power Assets theme has 49 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Power Assets Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Other Consideration for investing in Juno Stock
If you are still planning to invest in Juno Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Juno Therapeutics' history and understand the potential risks before investing.
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |